Antihaemophilic factor, plasma/albumin-free method experience assessed through ongoing post-authorisation safety surveillance

• References

• 1 Data on file. Baxter Healthcare Corporation.
• 2 Octocog alpha (recombinant human coagulation Factor VIII produced by recombinant DNA technology in chinese hamster ovary cells). Summary of product characteristics. Vienna, Austria: Baxter AG; 2007
• 3 Lassila R, Rothschild C, De Moerloose P. et al. on behalf of the European Haemophilia Therapy Standardization Board (EHTSB). Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 2005; 11: 353-359.
• 4 US Food and Drug Administration. Workshop on factor VIII inhibitors. http://www.fda.gov/cber/minutes/fctrviii112103t.htm. Accessed February 23, 2007.